The role of biotechnology during COVID-19

Main Article Content

Giovanni Garro-Monge

Abstract

Biotechnology is the application of science and technology to living organisms, as well as to parts, products, and models to alter living or non-living materials for the production of knowledge, goods, and services that benefit society. Precisely, this branch of science merges two of the most relevant areas that can provide valuable tools to help us fight against the SARS-CoV-2 pandemic. Among them are the applications of medical and plant biotechnology for the creation of a vaccine against the virus, where various institutions and biotechnology companies worldwide such as Pfizer and Medicago present promising results that are advancing towards advanced preclinical phases. Apart from this, various institutions have used alternative biotechnological techniques such as CRISPR gene editing to provide an alternative solution, such as Stanford University. However, the pandemic will also affect the economy, through which biotechnology can be of use especially in agricultural-based economies through advances in plant and food science. Precisely, at the national level for Costa Rica, it is estimated that the pandemic will have the highest impact in history on the economy of the Central American region. This will particularly affect the agricultural sector, an area where biotechnology offers promising solutions through technical advice regarding vitro plants, agrochemicals, and the most efficient and controlled use of resources. In short, today, more than ever, it is possible to demonstrate the importance of science, research and development and the fusion with the technologies offered by biotechnology to solve this global health and economic crisis.


 


 


 

Article Details

How to Cite
Garro-Monge, G. (2022). The role of biotechnology during COVID-19. Tecnología En Marcha Journal, 35(5), Pág. 15–24. https://doi.org/10.18845/tm.v35i2.5663
Section
Artículo científico
Author Biography

Giovanni Garro-Monge, Instituto Tecnológico de Costa Rica

Profesor Catedrático- Investigador

Escuela de Biología

References

F. Wu, S. Zhao, B. Yu,Y. Chen, Z. Song & M. Yuan. “A new coronavirus associated with human respiratory disease in China”. Nature, 579(7798), 265-269. 2020. [Online]. Disponible en: doi: 10.1038/s41586-020-2008-3.

World Health Organization. A Global Collaboration to Accelerate the Development, Production and Equitable Access to New COVID-19 diagnostics, therapeutics and vaccines. Abril. 15, 2020. [Online]. Disponible en: https://www.who.int/news/item/24-04-2020-commitment-and-call-to-action-global-collaboration-to-accelerate-new-covid-19-health-technologies

K. Andresen, A. Rambaut, I. Lipkin, E. Holmes, R. Garry. “The proximal origin of SARS-CoV-2”. Nature Medicine, 26, 450-452. 2020. [Online] Disponible en: doi: 10.1038/s41591-020-0820-9

B. Van Bezuzekom & A. Arundel OECD Biotechnology Statistics. 2009. [Online]. Disponible en: https://www.oecd.org/sti/42833898.pdf

T. Le, Z. Andreadakis, A. Kumar, R. Gomez, S. Tollefsen, M. Saville & S. Mayhew. “The COVID-19 vaccine development landscape”. Nature Reviews Drug Discovery, 19, 305-306. April 2020. [Online] Disponible en: doi: 10.1038/d41573-020-00073-5

T. Capell, R. Twyman, V. Najera, J. Ma, S. Schillberg & P. Cristou. “Potential applications of plant biotechnology against SARSCoV-2.” Trends in Plant Science, 25(7), 635-643. Abril 2020. [Online] Disponible en: doi: 10.1016/j.tplants.2020.04.009

S. Rosales, V. Márquez, O. Gonazlez, R. Nieto & J. Arévalo. “What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?”. Vaccines, 8(2), 183. Marzo 2020. [Online]. Disponible en: doi: 10.3390/vaccines8020183

M. Tahir ul Qamar, S. Alqahtani, M. Alamri & L. Chen. “Structural Basis of SARS-CoV-2 3CLpro and Anti-COVID-19 Drug Discovery from Medicinal Plants”. Journal of Pharmaceutical Analysis, 10(4), 313-319. Agosto 2020. [Online]. Disponible en: doi: 10.1016/j.jpha.2020.03.009.

Medicago. MEDICAGO AND GSK ANNOUNCE START OF PHASE 2/3 CLINICAL TRIALS OF ADJUVANTED COVID-19 VACCINE CANDIDATE. 2020. [Online]. Disponible en https://www.medicago.com/en/media-room/medicago-and-gsk-announce-start-of-phase-2-3-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/

P. Duddu. Coronavirus treatment: Vaccines/drugs in the pipeline for COVID-19. Abril. 16, 2020. [Online]. Disponible en: https://www.clinicaltrialsarena.com/analysis/coronavirus-mers-cov-drugs/

P. Naveira.Una planta de tabaco, clave para la vacuna de la COVID-19. 2020. [Online]. Disponible en: https://as.com/diarioas/2020/07/15/actualidad/1594799033_765875.html

J. Rice, WM. Ainley & P. Shewen. “Plant-made vaccines: biotechnology and immunology in animal health”. Animal Health Review, 6(2), 199-209. 2005. [Online]. Disponoble en: doi: 10.1079/ahr2005110.

S. Rosales. “Will plant-made biopharmaceuticals play a role in the fight against COVID-19?”. Taylor and Francis Public Health Emergency Collection, 1-4. Abril 2020. [Online]. Disponible en: doi: 10.1080/14712598.2020.1752177

L.Jackson, E. Anderson, N. Rouphael, P. Roberts et al. “An mRNA Vaccine against SARS-CoV-2 — Preliminary Report”. The New England Journal of Medicine. Julio 2020. [Online]. Disponible en: doi: 10.1056/NEJMoa2022483

J. Cohen. “Vaccine designers take first shots at COVID-19”. Science, 368 (6486), 14-16. 2020. [Online] Disponible en: doi: 10.1126/science.368.6486.14

. Naciones Unidas. Más de 820 millones de personas pasan hambre y unos 2000 millones sufren su amenaza. Julio. 15, 2019. [Online]. Disponible en: https://news.un.org/es/story/2019/07/1459231

S. Fan, W. Si, Y. Zhang. “How to prevent a global food and nutrition security crisis under COVID-19?” China Agricultural Economic Review, 12 (3), 471-480. 2020. [Online] Disponible en: doi: 10.1108/CAER-04-2020-0065

A. Vidayasagar. What Is CRISPR?. Abril. 21, 2018. [Online]. Disponible en: https://www.livescience.com/58790-crispr-explained.html

R. Abbot, G. Dhamdhere, Y. Liu, X. Lin, L. Goudy, L. Zeng & L. Q. “Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza”. bioRxiv, 2020. [Online]. Disponible en: doi.org/10.1101/2020.03.13.991307

J. Daley. CRISPR Gene Editing May Help Scale Up Coronavirus Testing. Abril. 23, 2020. [Online]. Disponible en: https://www.scientificamerican.com/article/crispr-gene-editing-may-help-scale-up-coronavirus-testing/

A. Hernández. COVID-10 Vaccines and Treatments through Biotechnology and Science. Marzo. 25, 2020. [Online]. Disponible en: https://www.croplifela.org/en/whats-new/links/covid-19-vaccines-and-treatments-through-biotechnology-and-science

J. Ahn, Y. Sohn, S. Lee, H. Cho, Y. Hyun, J. H. Baek . . . S, Kim. (13 de abril de 2020). “Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea”. Journal of Korean Medicine Science, 35(14), 149. Abril 2020. [Online] Disponible en: doi.org/10.3346/jkms.2020.35.e149.

I.F, Hung, K.To, C. Lee, K. Lung Lee, K. Chan, W. Yan, . . . B. Tang. “Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infections.” Clinical Infectious Diseases, 52(4), 447-456. 2011. [Online] Disponible en: doi: 10.1093/cid/ciq106.

Y. Cheng, R. Wong, Y. Soo, W. Wong, C. Lee, M. Ng . . . G. Cheng. “Use of convalescent plasma therapy in SARS patients in Hong Kong”. European Journal of Clinical Microbiology and Infectious Diseases, 24(2005), 44-46. Diciembre 2004. [Online]. Disponible en: doi.org/10.1007/s10096-004-1271-9.

J. Jiménez. La UCR avanza para crear un medicamente contra el COVID-19, esta vez, a partir de plasma equino. [Online]. Abril. 17, 2020. Disponible en: https://www.ucr.ac.cr/noticias/2020/04/17/la-ucr-avanza-para-crear-un-medicamento-contra-el-covid-19-esta-vez-a-partir-de-plasma-equino.html

J. Jiménez. Analysis Reveals UCR-Produced Coronavirus Serums Inhibit Virus. Julio. 28, 2020. [Online]. Disponible en: https://www.ucr.ac.cr/noticias/2020/07/28/analisis-revelan-que-los-sueros-contra-el-coronavirus-producidos-por-la-ucr-inhiben-el-virus.html

J. Mora. INSTITUTO CLODOMIRO PICADO: SUEROS ANTIOFÍDICOS PARA EL MUNDO. Abril. 18,2018. [Online]. Disponible en: http://www.proinnova.ucr.ac.cr/es/2018/04/19/instituto-clodomiro-picado-sueros-antiofidicos-para-el-mundo/

Genetic Engineering & Biotechnology News. NIG Joins Forces with Pharmaceutical Companies to Fight COVID-19. Abril. 20, 2020. [Online]. Disponible en: https://www.genengnews.com/news/nih-joins-forces-with-pharmaceutical-companies-to-fight-covid-19/

CEPAL. Dimensionar los efectos del COVID-19 para pensar en la reactivación. Abril. 21, 2020. [Online]. Disponible en: https://repositorio.cepal.org/bitstream/handle/11362/45445/4/S2000286_es.pdf

M. Sancho. COVID-19 golpea al agro por ¢14 mil millones; casi 7 mil personas afectadas. Abril. 16, 2020. [Online]. Disponible en: https://observador.cr/noticia/covid-19-golpea-al-

República. CON UNA INVERSIÓN DE ₡4.267 MILLONES, GOBIERNO IMPULSA PROGRAMA DE ALTA TECNOLOGÍA PARA SECTOR AGROPRODUCTIVO. Mayo. 15, 2020. [Online] Disponible en: https://www.presidencia.go.cr/comunicados/2020/05/con-una-inversion-de-%E2%82%A14-267-millones-gobierno-impulsa-programa-de-alta-tecnologia-para-sector-agroproductivo/

República. Planificación de la Ruta Económica Post-Covid 19. 2020. [Online]. Dispoble en: https://www.ict.go.cr/es/documentos-institucionales/material-de-apoyo-coronavirus/decreto-declaratoria-de-emergencia/1682-medidas-de-reactivacion/file.html